KraneShares Feature | Nasdaq Dorsey Wright

KraneShares Feature

Published: January 20, 2026

This content is for informational purposes only. This should not be construed as solicitation. The general public should consult their financial advisor for additional information related to investment decisions.

There were no changes to the KraneShares models this week.

Chinese equities were slightly muted over the past week. China recorded a $1.2 trillion trade surplus in 2025, a 20% year‑over‑year increase and the largest in its history, underscoring the country’s resilience amid U.S. tariff pressures (source: cnn.com). Over the past week, President Trump enacted another 25% tariff on Nvidia and AMD chips. The goal is to promote the development of domestic technological supply chains, as the tariffs would be suspended if companies meet the criteria for supporting U.S. supply‑chain building (source: cnn.com). However, the effects have largely gone unnoticed and have yet to make any material impact. We will continue providing updates as new information is made readily available. This week, we cover the:

The KraneShares MSCI All China Health Care Index ETF (KURE) reversed back up earlier this month and remains in a column of Xs. KURE maintains a strong fund score of 4.30, above what we consider “technically actionable”. The fund is facing near-term resistance at $19.25. If it moves up above $19.50, KURE will reverse back to a buy signal. The fund offers a very low correlation to broader US markets with a beta of 0.35. Additionally, KURE offers a yield of 4.16%. Initial support and the bullish support line can be seen at $17, with additional support at $16.25.

Back to report

DISCLOSURE

KraneShares has arranged with Dorsey, Wright & Associates (“DWA”) to provide this specialized Funds page on KraneShares sponsored products. The Point & Figure analysis, models and resulting rankings, including any information, data or commentary included herein, are created and provided solely by DWA. Such analysis, models, and rankings should not be considered an offer to purchase or sell, or a solicitation of an offer to buy or purchase any security. Unless otherwise stated, the examples presented do not take into consideration dividends, commissions, tax implications, or all potential transactions costs. Neither DWA, nor KraneShares themselves, through this Fund page, provide investment advice or recommendations regarding any security, fund or market. As the investment professional making the final decision with respect to allocations, including any related suitability, fiduciary or other legal obligation, please remember to adhere to all applicable laws, regulations, and rules including FINRA Rules 2090 and 2111 (Suitability), or other such similar rules and regulations. The percentage of the portfolio devoted to any Fund is at the sole discretion of the financial advisor or the customer, and not DWA or KraneShares. If you are not familiar with the Point & Figure methodology, we suggest you read “Point & Figure Charting, Fourth Edition” by Thomas J. Dorsey and visit the PnF University. If you are not familiar with the KraneShares products, we suggest you visit https://kraneshares.com/# or call (855) 857-2638. You should consider each KraneShares product’s investment objectives, risks, and charges and expenses carefully before investing. Contact KraneShares at (855) 857-2638 or info@kraneshares.com to obtain a prospectus, which contains this and other information about the KraneShares products. Read it carefully before you invest.